| Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan. | |
| | |
MedLine Citation:
|
PMID: 10929034 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This pilot study evaluated the efficacy of a new combination chemotherapy with a newly developed nitrosourea derivative ranimustine and evaluated the efficacy of interferon alpha (IFN-alpha) maintenance in previously untreated patients with multiple myeloma (MM). The induction therapy (ROAD-IN) was a 6-week regimen consisting of chemotherapy with ranimustine, vincristine (Oncovin), melphalan (Alkeran) and dexamethasone starting on day 1 and IFN-alpha, which was administered three times weekly for 3 weeks starting on day 22. This was repeated for three cycles. The responders were subsequently randomized into two groups that received or did not receive IFN-alpha as maintenance therapy. Of the 164 patients registered, 161 were evaluated. An objective response to induction therapy was seen in 75% of patients; complete remission (CR) in 38 (24%) and partial remission (PR) in 82 (51%). The median survival for all patients was 3.6 years from registration. The survival of responders (CR + PR) was significantly better than that of non-responders (median survival 4.3 years vs. 1.4 years; 7-year survival rate 32% vs. 9%; P < 0.0001). The IFN-alpha maintenance did not show any advantage for either response duration or survival. This pilot study demonstrated that a comparatively short period of induction therapy with the ROAD-IN regimen produced a rather high response rate and a similar survival rate to those achieved with other longer induction regimens, and that good responders to the initial therapy survived significantly longer than non-responders. |
| | |
Authors:
|
M Wada; H Mizoguchi; S I Kuriya; H Taguchi; T Kawamura; I Maekawa; C Shimazaki; Y Sato; Y Niho; T Miyazaki; A Shibata; T Kitani; N Hamajima; R Ohno |
Related Documents
:
|
21249514 - Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carci... 21166004 - Extending limits of resection for metastatic colorectal cancer: risk benefit ratio. 21264534 - Prognostic value of smac expression in rectal cancer patients treated with neoadjuvant ... 8229154 - Lymphoblastoid interferon in advanced breast cancer: a phase ii study. 11859574 - Clear cell sarcoma of the kidney in an adult. a case report. 9007114 - Phase i study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: British journal of haematology Volume: 109 ISSN: 0007-1048 ISO Abbreviation: Br. J. Haematol. Publication Date: 2000 Jun |
Date Detail:
|
Created Date: 2000-08-31 Completed Date: 2000-08-31 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 0372544 Medline TA: Br J Haematol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 805-14 Citation Subset: IM |
Affiliation:
|
Department of Haematology, Tokyo Women's Medical University, Tokyo, Japan. wada@dh.twmu.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
administration & dosage,
therapeutic use* Chi-Square Distribution Dexamethasone / administration & dosage Humans Interferon-alpha / administration & dosage* Logistic Models Melphalan / administration & dosage Multiple Myeloma / diagnosis, drug therapy* Muscle Proteins* Myeloma Proteins / diagnostic use Nitrosourea Compounds / administration & dosage Pilot Projects Prospective Studies Remission Induction Vincristine / administration & dosage |
| Chemical | |
Reg. No./Substance:
|
0/Interferon-alpha; 0/Muscle Proteins; 0/Myeloma Proteins; 0/Nitrosourea Compounds; 0/ROAD-IN protocol; 0/multiple myeloma M-proteins; 0/myomesin; 148-82-3/Melphalan; 50-02-2/Dexamethasone; 57-22-7/Vincristine; 58994-96-0/ranimustine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic ...
Next Document: Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in my...